Moderna, mRNA and bird flu

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Legislation that would block hospitals from transfusing blood containing COVID-19 antibodies or “synthetic mRNA” could have ...
The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.
BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.
Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.
Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...
"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...
A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 ...
The president announced a major AI investment project, which Oracle Chairman Larry Ellison said could be used to cure cancer.